Athersys (ATHX) Scheduled to Post Quarterly Earnings on Tuesday

Athersys (NASDAQ:ATHX) is set to post its quarterly earnings results after the market closes on Tuesday, November 6th. Analysts expect Athersys to post earnings of ($0.08) per share for the quarter.

Athersys (NASDAQ:ATHX) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter. Athersys had a negative return on equity of 61.52% and a negative net margin of 106.99%. The business had revenue of $19.39 million during the quarter, compared to analysts’ expectations of $12.82 million. On average, analysts expect Athersys to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Athersys stock opened at $1.90 on Tuesday. Athersys has a 12 month low of $1.29 and a 12 month high of $3.09. The company has a market cap of $268.85 million, a PE ratio of -6.55 and a beta of -0.61.



In related news, insider Laura K. Campbell sold 28,868 shares of the company’s stock in a transaction on Friday, August 10th. The stock was sold at an average price of $2.01, for a total transaction of $58,024.68. Following the transaction, the insider now owns 590,424 shares of the company’s stock, valued at $1,186,752.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP John J. Harrington sold 15,000 shares of the company’s stock in a transaction on Friday, September 14th. The stock was sold at an average price of $1.91, for a total value of $28,650.00. Following the transaction, the executive vice president now directly owns 684,320 shares in the company, valued at approximately $1,307,051.20. The disclosure for this sale can be found here. Insiders have sold 76,088 shares of company stock worth $149,487 in the last ninety days. 18.60% of the stock is currently owned by corporate insiders.

A number of brokerages recently weighed in on ATHX. Zacks Investment Research lowered Athersys from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 9th. BidaskClub raised Athersys from a “sell” rating to a “hold” rating in a report on Wednesday, September 26th. Finally, Maxim Group reaffirmed a “buy” rating and set a $6.00 price objective on shares of Athersys in a report on Wednesday, August 8th.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Recommended Story: Bear Market – How and Why They Occur

Earnings History for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply